Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.
3.

[Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].

Obradović S, Gligić B, Djordjević D, Jovicić A, Romanović R, Ratković N, Dincić D, Orozović V, Nikolić G.

Vojnosanit Pregl. 2001 Jan-Feb;58(1):65-72. Review. Serbian. No abstract available.

PMID:
11419288
4.

[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].

Araujo R, Agustí A.

Med Clin (Barc). 2000 Oct 7;115(11):435-7. Spanish. No abstract available.

PMID:
11093849
5.
6.

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.

Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.

7.

The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.

Lavi S, Gruberg L, Kapeliovich M, Hammerman H, Boulos M, Grenadier E, Aronson D, Markiewicz W, Beyar R.

J Invasive Cardiol. 2005 Jun;17(6):296-9.

PMID:
16003002
8.

Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).

Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV Jr, Ohman EM, Gibler WB, Roe MT.

Am J Cardiol. 2007 May 15;99(10):1389-93. Epub 2007 Mar 26.

PMID:
17493466
9.

[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].

Radke PW, Schunkert H.

Dtsch Med Wochenschr. 2006 Nov 24;131(47 Suppl 7):S204-7. Review. German. No abstract available.

PMID:
17109249
10.

Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

Roe MT, Sapp SK, Lincoff AM.

Cleve Clin J Med. 2000 Feb;67(2):131-40. Review.

PMID:
10680279
11.

Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.

Ben-Yehuda O.

J Am Coll Cardiol. 2006 Feb 7;47(3):538-40. Epub 2006 Jan 18. No abstract available.

12.

The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.

Moliterno DJ, Ziada KM.

J Am Coll Cardiol. 2008 Feb 5;51(5):536-7. doi: 10.1016/j.jacc.2007.10.025. No abstract available.

13.

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.

Adgey AA.

Eur Heart J. 1998 Apr;19 Suppl D:D10-21. Review.

PMID:
9597518
14.

[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.

Herz. 2003 Aug;28(5):393-403. Review. German.

PMID:
12928738
15.

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.

Lincoff AM, Califf RM, Topol EJ.

J Am Coll Cardiol. 2000 Apr;35(5):1103-15. Review.

16.

[Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].

Kala P, Poloczek M, Bocek O, Jerábek P, Neugebauer P, Kosová J, Semrád B.

Vnitr Lek. 2002 Aug;48(8):736-41. Czech.

PMID:
12425204
17.
18.

Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.

Maioli M, Zeymer U, van 't Hof AW, Gibson CM, Dudek D, Bellandi F, Noc M, Secco GG, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, De Luca G; EGYPT Cooperation.

J Invasive Cardiol. 2012 Jul;24(7):324-7.

19.

Mechanical reperfusion: treat well, treat on time too.

Montalescot G.

Lancet. 2008 Aug 16;372(9638):509-10. doi: 10.1016/S0140-6736(08)61211-8. No abstract available.

PMID:
18707968

Supplemental Content

Support Center